Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 243-248

  Jennings, Cormac J ^a   O'Grady, Anthony ^a   Cummins, Robert ^a   Murer, Bruno ^b   Al Alawi, Mazen ^a   Madden, Stephen F ^c   Mutti, Luciano ^d   Harvey, Brian J ^a   Thomas, Warren ^a   Kay, Elaine W ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b Dell'Angelo Hospital   (Italy)

^c DUBLIN CITY UNIVERSITY   (Ireland)

^d Local Health Unit 11   (Italy)

Author keywords

Estrogen receptor; Mesothelioma; Steroid receptor coactivator

Indexed keywords

ESTROGEN RECEPTOR BETA; NUCLEAR RECEPTOR COACTIVATOR 2; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; TUMOR BIOPSY;

EID: 84655160811     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822f6544     Document Type: Article

References (26)

1. Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005;10:266-283. (Pubitemid 41025602)
2. Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006;103:14128-14133. (Pubitemid 44452991)
3. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007;7:147-154. (Pubitemid 46160990)
4. Steele JP. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 2005;19:1041-1052, vi. (Pubitemid 41736041)
5. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary eferral center. J Thorac Oncol 2007;2:957-965. (Pubitemid 47511601)
6. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310 -317; discussion 317-318.
7. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-735. (Pubitemid 30660898)
8. Pinton G, Brunelli E, Murer B, et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 2009;69:4598-4604.
9. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999;20:321-344. (Pubitemid 30649811)
10. Onate SA, Tsai SY, Tsai MJ, et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270:1354-1357.
11. Voegel JJ, Heine MJ, Zechel C, et al. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996;15:3667-3675. (Pubitemid 26239779)
12. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-968. (Pubitemid 27366683)
13. Zhou P, Chen MH, McLeod D, et al. Predictors of prostate cancerspecific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23:6992-6998.
14. Torres-Arzayus MI, Font de Mora J, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-274. (Pubitemid 39222039)
15. Bardin A, Boulle N, Lazennec G, et al. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004;11:537-551. (Pubitemid 39331282)
16. Foley EF, Jazaeri AA, Shupnik MA, et al. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000;60:245-248. (Pubitemid 30070743)
17. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, et al. Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis 2009;24:613-622.
18. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206. (Pubitemid 23046895)
19. Harrington DP, Fleming TR. A class of rank procedures for censored survival data. Biometrika 1982;69:553-566.
20. Andersen PK, Gill RD. Cox's regression model for counting processes, a large sample study. Ann Stat 1982;10:1100-1120.
21. Singh S, Poulsom R, Hanby AM, et al. Expression of oestrogen receptor and oestrogen-inducible genes pS2 and ERD5 in large bowel mucosa and cancer. J Pathol 1998;184:153-160. (Pubitemid 28088423)
22. Al-azawi D, Ilroy MM, Kelly G, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008;27:3021-3031. (Pubitemid 351668011)
23. Pinton G, Thomas W, Bellini P, et al. Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One 2010;5:e14110.
24. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-428. (Pubitemid 38114127)
25. Strom A, Hartman J, Foster JS, et al. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1566-1571. (Pubitemid 38236167)
26. Cheng J, Lee EJ, Madison LD, et al. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004;566:169-172. (Pubitemid 38625953)